NCT02443168View on ClinicalTrials.gov

Radiolabeled Study of AG-221 in Healthy Male Subjects.

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

May 14, 2015

Primary Completion Date

July 21, 2015

Study Completion Date

July 21, 2015

Conditions

Healthy Volunteers

Interventions

DRUG

AG-221

Part 1: oral solution containing 100 mg \[14C\]-AG-221

RADIATION

14C AG-221

5 mL of 100 micrograms \[14C\] AG-221 given intravenously 4 hours after swallowing the formulated tablet.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Celgene

INDUSTRY